First‐Line Lorlatinib in Striatin–Anaplastic Lymphoma Kinase‐Positive Lung Adenocarcinoma: A Case Report and Literature Review
Masaru Maebeya, Shinobu Tamura, Takeshi Shono, Takanobu Hoso, Hitomi Tatsuta · 2026
Read First‐Line Lorlatinib in Striatin–Anaplastic Lymphoma Kinase‐Positive Lung Adenocarcinoma: A Case Report and Literature Review by Masaru Maebeya, Shinobu Tamura, Takeshi Shono, Takanobu Hoso, Hitomi Tatsuta (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13541762.txt.
Description
Masaru Maebeya and co-authors report a lung cancer case with a rare gene fusion in a 2026 paper. The patient, a 45-year-old man, had lung adenocarcinoma driven by a striatin-ALK fusion, a variant so rare that the best first drug was unclear.
His cancer had already spread to the brain, which doctors treated with focused radiation. He then started lorlatinib, a drug built for ALK-driven tumors, as his first medicine. Nerve and mood side effects forced the dose down in steps, yet the cancer shrank and stayed controlled in body and brain for over a year. The case supports lorlatinib as a first choice for this rare subtype.
Catalog record
| CREATOR | Masaru Maebeya, Shinobu Tamura, Takeshi Shono, Takanobu Hoso, Hitomi Tatsuta |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |